On May 5, 2017 a New Horizons in Nephrology: Updates in Onco-Nephrology Symposium took place at the Gift of Life Institute in Philadelphia, PA, USA. The symposium chair, Dr. Jonathan Hogan, along with the organizing committee, put together an excellent program with expert local faculty from the Renal, Electrolyte and Hypertension Division, Perelman School of Medicine/University of Pennsylvania as well as visiting faculty. This conference reflects the importance of this rapidly growing subfield known as Onco-Nephrology, which combines the unique knowledge and efforts of members from a number of specialty groups, including nephrology, oncology, urology, pharmacology, critical care medicine, and palliative care medicine (1) .
To provide cutting edge care to this group of complex patients with cancer and kidney disease, clinicians and other health care providers need to develop a strong knowledge base and level of competence. This includes developing a comprehensive understanding of the pathophysiology of various forms of kidney disease that occurs in cancer patients. In addition, health care providers must accumulate the appropriate knowledge base and clinical skills to yield outstanding diagnostic and management skills for the spectrum of kidney disease that develops in patients with malignant processes can promote end-organ injury, such as a cardiomyopathy and acute kidney injury (AKI). Prevention of these complications includes pretreatment chemotherapy to reduce the tumor burden, and steroids to blunt the effect of cytokines (4) (5) (6) (7) (8) (9) (10) (11) . Standard supportive measures include vasopressors, intravenous fluids, and oxygen therapy. When severe cytokine release syndrome and macrophage activation syndrome develop, tocilizumab (interleukin [IL]-6 receptor blocker) and/or steroids are employed to reduce adverse effects (4) (5) (6) (7) (8) (9) (10) (11) . As outlined by the authors, the future potential of CAR T-cell therapies is exciting.
Another important subject discussed in this compendium of articles is an update on the adverse renal effects of various anticancer agents. In my lecture entitled "Update on the renal effects of anti-cancer agents," I reviewed the kidney lesions that occur with medications from 3 categories: (i) conventional chemotherapy; (ii) targeted anti-cancer agents; and (iii) novel immunotherapies. Conventional chemotherapeutic agents are relatively well known by the nephrology and oncology communities. Renal vascular, glomerular, tubular, and interstitial injury can occur with these drugs (12, 13) . Thrombotic microangiopathy (TMA) from gemcitabine, the result of a direct cytotoxic effect on endothelial cells, has been described in cancer patients (14) . AKI, hypertension, and microangiopathic hemolytic anemia with thrombocytopenia characterizes this lesion. Therapies are primarily supportive, including renal replacement therapy for those with severe AKI and permanent end-stage renal disease (ESRD). Pamidronate is associated with AKI and nephrotic proteinuria from drug-induced podocytopathy (15) Focal and segmental glomerulosclerosis (FSGS) is more commonly seen than minimal change disease (MCD). The lesion is modestly responsive to corticosteroids and many patients are left with chronic kidney disease (CKD) or ESRD. Zoledronate causes primarily AKI from toxic acute tubular injury. High-dose methotrexate causes AKI from a crystalline nephropathy as methotrexate is insoluble in acidic urine and precipitates within tubular lumens (16) . Prevention mandates bicarbonate-containing intravenous fluids, while therapy includes leucovorin rescue and individualized use of hemodialysis and glucarbidase to lower toxic methotrexate levels (17, 18) . Targeted drugs are an important part of the armamentarium to treat malignancies (19) . Antiangiogenesis agents are effective for a number of cancers. However, they are associated with proteinuria, hypertension, and AKI, which is frequently due to a TMA and less commonly acute interstitial nephritis (AIN) (20, 21) . The tyrosine kinase inhibitors targeting the vascular endothelial growth factor pathway also have been shown to develop an FSGS lesion more commonly than a TMA lesion (22) . The treatment of TMA mandates drug discontinuation while proteinuria and hypertension can be managed with antihypertensive agents (ACE-inhibitors, angiotensin receptor blockers, and calcium channel antagonists) (23) . The epidermal growth factor receptor inhibitors are associated with hypomagnesemia due to the blunting of TRP-M6 (magnesium) channel function (24, 25) . Other targeted anticancer agents include the BRAF and ALK inhibitors, which are associated with AKI and other kidney lesions (26, 27) . Tubulointerstitial injury appears to be the primary kidney lesion associated with these drugs. A rapidly expanding area in cancer therapeutics is the use of immunotherapies. These drugs leverage the immune system to destroy cancer cells. Early cytokine therapies included interferon (28) , which is associated with a podocytopathy (MCD and FSGS) and TMA, and high-dose IL-2, which causes a capillary leak syndrome with associated prerenal azotemia and ischemic acute tubular injury (ATI) (29) . Immune checkpoint inhibitors are a class of drugs (monoclonal antibodies) that activate and release T-cells from inhibition by blocking the cytotoxic T lymphocyte-associated antigen 4 and programmed death-1 protein receptors from binding either dendritic or tumor cell ligands (30, 31) . This effect restores antitumor immunity and enhances tumor killing, but also promotes loss of self-tolerance thereby risking pathologic autoimmunity and end-organ injury. These drugs have been most commonly associated with AIN, which is sometimes granulomatous. However, immune-complex glomerular disease and MCD also have been rarely described.
As noted by the article title, "Demystifying the monoclonal gammopathies of renal significance (MGRS)," Dr. Hogan describes the differences between this entity and the generally benign monoclonal gammopathy of undetermined significance (MGUS). Simply stated, MGRS are paraproteinmediated diseases of the kidney that develop in patients who do not meet criteria for multiple myeloma, systemic lymphoma, or amyloidosis (32) . This is an important distinction as MGUS requires ongoing observation, while MGRS mandates therapy to eradicate the clonal population producing kidney injury (33) . As pointed out in this article, MGRS is associated with a number of kidney lesions most commonly including those noted in (Tab. I). Dr. Hogan clearly "demystifies" the evaluation and treatment of disorders associated with MGRS. Paraprotein basics are initially reviewed for the reader explaining the paraprotein structure, the serum and urine testing, and the potential for endorgan damage. A brief primer on MGRS follows, emphasizing the role of kidney biopsy to make a definitive diagnosis. Dr. Hogan describes the light, immunofluorescence, and electron microscopy images of the various kidney lesions caused by monoclonal protein deposition. An elegant discussion of the work-up and identification of the circulating paraprotein and underlying B-cell or plasma cell clone (including bone marrow biopsy) is then undertaken. The paper ends with a thoughtful discussion of the treatment of patients with MGRS. Important points include (i) paraproteins can induce kidney injury regardless of their size; and (ii) patients with small or undetectable paraprotein clones may still require therapy to eradicate the B-or plasma cell clone. Response to therapy is measured by a number of factors, such as improvement in paraprotein levels, reductions in proteinuria, and improvement in kidney function (34) (35) (36) .
As noted by the title of the paper, "Kidney disease in cancer survivors: focus on hematopoietic stem cell transplant" is an important topic for nephrologists, oncologists and HSCT specialists. Drs. Laskin and Jodele review kidney disease that develops in patients who are surviving their battle with cancer following HSCT. Kidney disease (Tab. II) is an important complication of cancer therapy with HSCT, which is, in part, related to chemotherapy, various nephrotoxins, infections, and other exposures (37) . They note that acute and chronic kidney disease in this setting are associated with increased morbidity and mortality in both children and adults. The focus of the paper is on 2 specific kidney lesions that develop following HSCT: TMA and BK virus nephropathy. The authors review some of the published literature on outcomes following HSCT, pointing out that CKD occurs in approximately 20% of patients following HSCT, while AKI -in particular dialysis-requiring AKI -is associated with increased mortality (37) . With regard to classifying CKD in this group of patients, serum Cr-based glomerular filtration rates (GFR) estimates are fraught with error. The authors note that using cystatin C (or adding to creatinine) in GFR estimating formulae does not improve the test in adults (38) . In contrast, the CKD Children Formula (CKDCF) provided GFR estimates that were not significantly different than measured GFR in children (39) . The authors describe that the increase in blood pressure is an important early signal to the development of TMA before other clinical and laboratory findings developa finding that can be quite useful for clinicians managing HSCT patients (40) . Furthermore, patients with clinical evidence of TMA (proteinuria and elevated sC5b-9) have worst survival, and these 2 findings, along with testing for regulatory complement mutations, may help with the risk stratification of these patients (41, 42) . The authors posit that BK virus-associated kidney disease is under-recognized in HSCT patients. They note that measuring blood BK virus is the most sensitive and specific test for BK virus infection, but caution that kidney biopsy is required for the definitive diagnosis of BKV nephropathy. Recognizing the challenge of kidney biopsy in these patients, the authors also review the potential of examining the urine with electron microscopy (EM) to identify polyoma-Haufen (casts of viral aggregates) as a noninvasive diagnostic tool (43) . I hope the JON readers find this series of papers from lectures delivered at the New Horizons in Nephrology: Updates in Onco-Nephrology Symposium educational and of practical value. This will improve the provision of care for commonly encountered onco-nephrology problems similar to those discussed in this Onco-Nephrology Highlights.
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